Pharmaceutical Stocks Witness Significant Surge Amid Market Weakness

Nifty Pharma Index Performance

The share prices of various pharmaceutical companies demonstrated a marked increase, as the Nifty Pharma index rose by 2% on the National Stock Exchange (NSE) despite an overall weak market environment.

As of 01:50 PM on Monday, the Nifty Pharma index was reported at 26,099.30, reflecting a gain of 1.77 percent, while the Nifty 50 faced a decline of 0.35 percent. The pharma index reached an intraday high of 26,126.20 and is approaching its previous record high of 26,135.75, recorded on July 16, 2026.

Several firms, including Torrent Pharmaceuticals, Mankind Pharma, Cipla, Laurus Labs, Aurobindo Pharma, Wockhardt, Sai Life Sciences, Alkem Laboratories, Divis Laboratories, Lupin, and Dr. Reddy’s Laboratories, experienced a surge in stock prices ranging between 2 percent and 5 percent during intraday trading.

In addition, RPG Life Sciences, Thyrocare Technologies, Hester Biosciences, Rubicon Research, IOL Chemicals & Pharmaceuticals, Emcure Pharmaceuticals, Themis Medicare, and Suven Life Sciences saw stock increases of between 4 percent and 8 percent according to the BSE Healthcare index.

Rating Initiated for Emcure Pharmaceuticals

Motilal Oswal Financial Services has initiated coverage on Emcure Pharmaceuticals with a ‘Buy’ rating, acknowledging the company’s diversified domestic operations focused on women’s health and notable expansions in cardiology, CNS, anti-diabetes, HIV, and oncology.

The firm highlighted Emcure’s strong brand growth, investments in physician coverage, and partnerships aimed at high return on capital employed (RoCE) strategies. Analysts predict an 11 percent compound annual growth rate (CAGR) in domestic sales, estimating revenues to reach ₹4,900 crore by FY28E.

Despite moderate financial performance in FY23 and FY24 due to heightened investments, Emcure is projected to deliver improved financial results in FY25 and FY26, bolstered by a strong presence in international markets, complemented by inorganic growth and favorable currency conditions.

Motilal Oswal expects revenue, EBITDA, and profit after tax (PAT) to grow at CAGRs of 14 percent, 20 percent, and 28 percent, respectively, over FY26-28, predicting figures of ₹11,900 crore, ₹2,600 crore, and ₹1,450 crore.

The company’s robust earnings base, averaging 20 percent return on equity (RoE) over FY26-28, led to the assignment of an industry-level price-to-earnings (PE) multiple of 28x, resulting in a target price of ₹2,260 for Emcure stock.

Pharmaceutical Sector Overview and Market Outlook

The global macroeconomic landscape is characterized by rapid changes amid geopolitical conflicts and evolving trade relations. In contrast, the Indian pharmaceuticals market has shown resilience, with an 8.6 percent expansion over the past year as detailed in RPG Life Sciences’ FY26 annual report.

RPG Life Sciences’ stock price climbed to a record high of ₹3,063.60, marking a 7 percent increase during intraday trading. Over the last month, the stock has surged by 33 percent, juxtaposed against a mere 1 percent rise in the Nifty 50.

The overall market outlook remains positive, with increasing healthcare awareness, improved accessibility to quality treatment, continuous innovation, advancing healthcare infrastructure, and a heightened focus on chronic disease management providing a solid foundation for long-term industry growth, according to RPG Life Sciences.

The company aims to enhance the distribution of existing and new products across multiple countries, including those in the European Union, while expanding its offerings in the UK, Australia, Canada, Myanmar, and other emerging markets. Furthermore, governmental initiatives to develop active pharmaceutical ingredients (APIs) and reduce import reliance enhance the strategic value of the business.

Meanwhile, Torrent Pharmaceuticals indicated in its FY26 annual report that future global medicine usage will be shaped by patient-centric innovation in therapies, expanded access in emerging markets via biosimilars and generics, and enhanced therapeutic engagement in complex disease management.

Market analysts from BNP Paribas India noted that Indian generic pharmaceutical companies are shifting focus to the global biosimilar market, particularly in the US and EU, with the anticipation that upcoming patent expirations will present substantial growth opportunities.

Despite potential market challenges as companies may enter competitive landscapes later than anticipated, the long-term prospects for biosimilars are anticipated to positively impact profitability gradually.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The AdTech365 Mobile app, for fast, crisp, clean updates!

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share